242 related articles for article (PubMed ID: 12817897)
21. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Horikawa M; Kato Y; Sugiyama Y
Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
[TBL] [Abstract][Full Text] [Related]
22. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
23. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
24. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
[TBL] [Abstract][Full Text] [Related]
25. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
26. In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay.
Rabba AK; Si L; Xue K; Li M; Li G
J Pharm Pharm Sci; 2011; 14(2):138-47. PubMed ID: 21733405
[TBL] [Abstract][Full Text] [Related]
27. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
[TBL] [Abstract][Full Text] [Related]
28. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
[TBL] [Abstract][Full Text] [Related]
29. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
Kroetz DL
J Clin Oncol; 2006 Sep; 24(26):4225-7. PubMed ID: 16895999
[No Abstract] [Full Text] [Related]
30. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Tokuriki M; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2004 Apr; 124(3):313-7. PubMed ID: 15141761
[TBL] [Abstract][Full Text] [Related]
33. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.
Gotoh Y; Suzuki H; Kinoshita S; Hirohashi T; Kato Y; Sugiyama Y
J Pharmacol Exp Ther; 2000 Jan; 292(1):433-9. PubMed ID: 10604980
[TBL] [Abstract][Full Text] [Related]
34. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
BMC Med; 2004 May; 2():16. PubMed ID: 15125776
[TBL] [Abstract][Full Text] [Related]
35. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2.
Jedlitschky G; Leier I; Buchholz U; Hummel-Eisenbeiss J; Burchell B; Keppler D
Biochem J; 1997 Oct; 327 ( Pt 1)(Pt 1):305-10. PubMed ID: 9355767
[TBL] [Abstract][Full Text] [Related]
36. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
Lin LC; Wang MN; Tsai TH
Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
[TBL] [Abstract][Full Text] [Related]
37. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
38. P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.
Zhang Y; Wang C; Liu Z; Meng Q; Huo X; Liu Q; Sun P; Yang X; Sun H; Ma X; Liu K
Pharmacol Rep; 2018 Apr; 70(2):243-250. PubMed ID: 29475007
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
[TBL] [Abstract][Full Text] [Related]
40. Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat.
Jäger W; Winter O; Halper B; Salamon A; Sartori M; Gajdzik L; Hamilton G; Theyer G; Graf J; Thalhammer T
Hepatology; 1997 Dec; 26(6):1467-76. PubMed ID: 9397986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
